Weekly View

ICER Weekly View: August 23, 2019

From the desk of David Whitrap ICER proposed updates to our 2020 Value Assessment Framework this week – including new emphasis on real-world evidence, a revised approach to voting on contextual considerations, and a formal process for re-evaluating evidence report 12 months after our reports are published. These proposals are based on ICER’s experience in […]

Read More

ICER Weekly View: August 16, 2019

From the desk of David Whitrap Good morning everyone. This week, The New York Times Editorial Board provided some important recommendations for how the US should evaluate rare-disease treatments when the basic clinical evidence is still emerging – to better balance the safety, innovation, and affordability we all want from our health care. In some […]

Read More

ICER Weekly View: August 9, 2019

From the desk of David Whitrap This week the FDA announced that Novartis recently informed the agency of a data manipulation issue that affects the accuracy of certain animal testing data related to Zolgensma, the company’s gene therapy for spinal muscular atrophy. ICER is deeply concerned about issues related to data integrity, and we’re monitoring […]

Read More

ICER Weekly View: August 2, 2019

From the desk of David Whitrap Good morning everyone. For ICER’s 2019 Visiting Fellows Program, we invited top health economists from around the world — including Karl Claxton, PhD, MSc, from the University of York; Jens Grueger, PhD, President-elect of the International Society for Pharmacoeconomic Outcomes Research (ISPOR); Sean Sullivan, PhD, MS, from the University […]

Read More

ICER Weekly View: July 26, 2019

From the desk of David Whitrap Yesterday, ICER hosted a public meeting to review the clinical evidence, non-clinical benefits, and cost-effectiveness of treatments for Duchenne muscular dystrophy. This is a truly horrible disease for boys, and the parent testimony shared throughout the day anchored the conversation and brought tears to several members of our independent […]

Read More

ICER Weekly View: July 19, 2019

From the desk of David Whitrap Hello everyone. As you sip your morning cup of coffee, just remember that personal finance gurus really, really wish you would’ve brewed it yourself at home. This week, let’s take a look at: ICER in the News: An NPR profile about ICER’s growth into an important watchdog; and ICER’s […]

Read More

ICER Weekly View: July 12, 2019

From the desk of David Whitrap Good morning everyone. This week, influential minds from both ends of the political spectrum delivered new recommendations for how the US could lower drug costs. And while there is predictable disagreement between their respective approaches, both sides feature ICER as part of the solution… The left-leaning New York Times […]

Read More

ICER Weekly View: June 28, 2019

From the desk of David Whitrap Good morning everyone. The Weekly View will be on break next week but will be back in your inbox on July 12. Have a fun-filled Fourth! This week, let’s take a look at: ICER in the News: WBUR’s deep dive into ICER’s role in the US health care system, […]

Read More

ICER Weekly View: June 21, 2019

From the desk of David Whitrap Good morning everyone. Busy week, so let’s get right into the news coverage: ICER in the News: The Boston Globe’s front-page profile of ICER’s growing influence, and our Final Evidence Reports on both Spravato (for treatment-resistant depression) and Mayzent (for secondary progressive multiple sclerosis). Pharmaceutical News: Recapping all the […]

Read More

ICER Weekly View: June 14, 2019

From the desk of David Whitrap Hello everyone. Across all four major US sports leagues, it’s been more than 25 years since a Canadian team captured a championship. Well, at least that was the case until last night when the Toronto Raptors won their first-ever NBA Finals. Separately, across all four major US sports leagues, […]

Read More

Sign-up to have the Weekly View delivered to your inbox every Friday morning.

SIGN UP